News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
05-May-2011 - Intercell AG announced the start of a further trial in the field of pandemic Influenza, investigating Intercellʹs adjuvant patch (Vaccine Enhancement Patch ‐ VEP) containing LT (a heat‐labile toxin from E. coli) in combination with GSKʹs H5N1 pandemic antigen. This trial follows prior work with a ...
04-May-2011 - Astex Therapeutics announced that it has achieved multiple early milestones in its fragment-based drug discovery collaboration with GlaxoSmithKline which commenced in November 2009. Total milestone payments received under the collaboration have now reached £5.9 million. The milestones relate to ...
08-Mar-2011 - Galapagos NV announced that it delivered a fourth candidate drug in its arthritis alliance with GlaxoSmithKline (GSK) in December 2010. This achievement triggered a €6.7 million milestone payment to Galapagos, which was included in 2010 revenues. This latest pre-clinical candidate is a small ...
07-Mar-2011 - AFFiRiS AG announced significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical ...
11-Feb-2011 - Cellzome announced today that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone triggers a payment of an undisclosed amount from GSK and follows only two months after the first milestone was achieved.The strategic collaboration in epigenetics was ...
01-Feb-2011 - McGill University and GlaxoSmithKline plc (GSK) have signed a collaboration agreement to develop a potential breakthrough approach to treat cystic fibrosis, a fatal genetic disease. The trans-Atlantic effort between researchers from McGill's Faculty of Medicine and their GSK collaborators in the ...
31-Jan-2011 - Actelion Ltd and GlaxoSmithKline announced that clinical development of the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued. This decision follows a review of data from additional clinical studies, which were conducted to further establish the ...
21-Jan-2011 - GlaxoSmithKline (GSK) and Prosensa announced that the first patient has commenced treatment in the Phase III clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy (DMD), who have a dystrophin gene mutation amenable to an exon 51 skip (up to 13% of boys with ...
12-Jan-2011 - Galapagos NV announced progress achieved in its arthritis alliance with GlaxoSmithKline (GSK). Galapagos completed first-in-human trials with GLPG0555 in healthy volunteers. Galapagos also initiated clinical Phase I development for a second candidate drug, GLPG0778, which triggered a milestone ...
11-Jan-2011 - Immutep S.A. announced the execution of a licence agreement granting GSK exclusive worldwide rights to ImmuTune(R) IMP731 and any other antibodies that deplete LAG-3 positive cells. IMP731 has demonstrated potency at low doses in preclinical models of T-cell mediated inflammation and could ...
© 1997-2024 LUMITOS AG, All rights reserved